We report that artemin, a member of the glial cell linederived neurotrophic factor family of ligands, is oncogenic for human mammary carcinoma. Artemin is expressed in numerous human mammary carcinoma cell lines. Forced expression of artemin in mammary carcinoma cells results in increased anchorage-independent growth, increased colony formation in soft agar and in three-dimensional Matrigel, and also promotes a scattered cell phenotype with enhanced migration and invasion. Moreover, forced expression of artemin increases tumor size in xenograft models and leads to highly proliferative, poorly differentiated and invasive tumors. Expression data in Oncomine indicate that high artemin expression is significantly associated with residual disease after chemotherapy, metastasis, relapse and death. Artemin protein is detectable in 65% of mammary carcinoma and its expression correlates to decreased overall survival in the cohort of patients. Depletion of endogenous artemin with small interfering RNA, or antibody inhibition of artemin, decreases the oncogenicity and invasiveness of mammary carcinoma cells. Artemin is therefore oncogenic for human mammary carcinoma, and targeted therapeutic approaches to inhibit artemin function in mammary carcinoma warrant consideration.
Introduction
Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFL), a distant subgroup of the transforming growth factor b superfamily, include four members: GDNF, neurturin, artemin and persephin (Airaksinen et al., 1999; Airaksinen and Saarma, 2002) .
All GFLs are potent neurotrophic factors (Airaksinen and Saarma, 2002) . GDNF was identified as a trophic factor for midbrain dopaminergic neurons (Lin et al., 1993) . It promotes survival of many types of neurons, including subpopulations of peripheral autonomic and sensory, as well as central motor, dopamine and noradrenaline, neurons (Airaksinen et al., 1999) . GDNF, neurturin and artemin all support the survival of peripheral sympathetic and sensory neurons, as well as midbrain dopamine neurons, whereas persephin supports central nervous system dopamine and motor neurons, but not peripheral neurons (Airaksinen et al., 1999) .
GDNF family ligands signal through a multicomponent receptor complex, which includes a glycosyl-phosphatidylinositol (GPI)-anchored co-receptor a (termed GFRa) as a ligand-binding component and the RET receptor tyrosine kinase as a common signaling component (Takahashi, 2001) . Binding of GFLs to a specific GFRa determines the signaling specificity of the receptor complex: GDNF preferentially binds to GFRa1, neurturin to GFRa2, artemin to GFRa3 and persephin to GFRa4 (Airaksinen and Saarma, 2002) . However, these binding specificities are not exclusive. For example, GDNF can also bind to GFRa2 and GFRa3 and artemin to GFRa1 (Bespalov and Saarma, 2007) . Apart from the GFRa-RET signaling mechanism, RET-independent signaling pathways have also been described (Poteryaev et al., 1999; Trupp et al., 1999; Meng et al., 2001b; Paratcha et al., 2003; Popsueva et al., 2003; Sariola and Saarma, 2003; Enomoto et al., 2004) . GDNF, for example, has been shown to activate cytoplasmic Src family tyrosine kinases through GFRa1 in RET-deficient cells (Poteryaev et al., 1999) .
Some evidence also links GFLs to cancer. Targeted expression of GDNF in undifferentiated spermatogonia promotes malignant testicular tumors (Meng et al., 2000 (Meng et al., , 2001a . GDNF has also been reported to promote tumor cell invasion in pancreatic cancer cell lines (Okada et al., 1999; Zhu et al., 2001; Veit et al., 2004) . GDNF and artemin are expressed in pancreatic cancer and influence neural invasion of the tumor, contributing to cancer cell spreading along pancreatic nerves (Ito et al., 2005; Ceyhan et al., 2006 Ceyhan et al., , 2007 . Furthermore, mutation of the common GFL receptor RET results in its constitutive activation, leading to thyroid cancer, pheochromocytoma and multiple endocrine neoplasia type 2 (MEN2) (MEN2A and MEN2B) (Pasini et al., 1996; Saarma and Sariola, 1999; Ichihara et al., 2004) .
We demonstrate herein that forced expression of artemin in mammary carcinoma cells increased oncogenicity, resulted in increased invasion and increased tumor growth in xenograft models. Depletion or functional inhibition of artemin in mammary carcinoma cells concordantly reduced their oncogenic properties. Artemin expression in breast cancer predicted metastasis, residual disease after chemotherapy, recurrence and death. We thereby provide evidence that artemin is important in human mammary neoplastic processes.
Results

Expression of artemin in human tissues and carcinoma cell lines
We first determined the expression profile of artemin in normal human tissues by the use of a commercially available panel of cDNAs ( Figure 1a ). Screening for mRNA expression by PCR with primers specific for human artemin revealed that the artemin gene is also expressed in a number of non-neural tissues, with highest expression observed in the cerebellum followed by the colon. Expression was also detected in the prostate, uterus, stomach, kidney, trachea, fetal brain, adipose and cartilage. Artemin was not expressed or expressed at a low level in other remaining tissues.
The expression of artemin in a number of human cancer cell lines was also examined by reverse transcription (RT)-PCR. As observed in Figure 1b , artemin was expressed in all the cancer cell lines examined. Highest expression was detected in DLD-1 colon, PC3 prostate and RL95-2 endometrial carcinoma cell lines. Moderate expression was observed in the BxPC3 pancreas carcinoma cell line and in four breast cancer cell lines, of which two (T47D and MCF-7) are estrogen receptor (ER) þ and two (BT549 and MDA-231) are ERÀ. Limited, but detectable, expression was observed in A549 lung, AGS stomach, Colo320DM colon, DU145 prostate and HepG2 liver cancer cell lines.
The expression of GFRa isoforms and RET was also determined by RT-PCR in MCF-7, T47D and BT549 mammary carcinoma cells (Figure 1c) . Expression of GFRa1, GFRa3 and RET was easily detected in MCF-7 cells, whereas expression of GFRa2 was weak and required more cycles to detect. GFRa4 was not detected in any of the three cell lines. The expression pattern of these receptors in T47D and BT549 cells was quite similar to that in MCF-7 cells, except that T47D exhibited a much lower level of GFRa1 expression and BT549 exhibited considerably higher expression of GFRa2.
Effect of forced expression of artemin on mammary carcinoma cell number A cell model system was established to determine the functional consequences of artemin expression in mammary carcinoma cells. MCF-7 cells were stably transfected with the artemin expression plasmid pIRESneo3-ARTN (designated as MCF7-ARTN) or with the empty vector pIRESneo3 (designated as MCF7-Vec). The forced expression of artemin in MCF7-ARTN cells was verified at both the mRNA (Figure 2a ) and protein (middle panel, Figure 2b ) levels compared with control MCF7-Vec cells. Forced expression of artemin also resulted in increased artemin protein in conditioned media (top panel, Figure 2b ).
We first determined whether forced expression of artemin affected total mammary carcinoma cell number in monolayer culture. Forced expression of artemin in MCF-7 cells did not significantly increase cell number under serum-replete conditions over a period of 8 days (Figure 2c ). However, in serum-reduced (0.2%) media, MCF7-ARTN cells increased in number significantly faster than did MCF7-Vec cells (Figure 2d) , with a 23% increase in total cell number relative to MCF7-Vec after 8 days (Po0.05). Forced expression of artemin in MCF-7 cells did not affect entry into S-phase, as assessed by bromodeoxyuridine (BrdU) incorporation (Figure 2e ).
Forced expression of artemin increased cell survival
The effect of forced expression of artemin on the survival of MCF-7 cells in serum-deprived conditions was examined by two different methods. Estimation of apoptosis with Hoechst 33258 dye (Figure 2f ) showed a significant reduction in apoptosis in MCF7-ARTN cells versus MCF7-Vec cells (Po0.05). Phosphatidylserine externalization is a unique marker for apoptosis; labeling of cells with fluorescein isothiocyanate-conjugated annexin V and propidium iodide (PI) revealed that MCF7-ARTN cells were resistant to serum-deprivation- induced apoptosis compared with control MCF7-Vec cells (Figure 2g ). There was little difference in terms of late apoptosis (annexin V-positive and PI-positive), 4.4% in MCF7-Vec cells and 3.5% in MCF7-ARTN cells. However, early apoptosis (annexin V-positive and PI-negative) was decreased from 3.7% for MCF7-Vec cells to 1.4% for MCF7-ARTN cells, suggesting that forced expression of artemin preferentially protected cells from early apoptosis.
Forced expression of artemin increased BCL2 gene expression Real-time PCR (see Supplementary data 2) was performed to determine the effect of forced expression of artemin on the relative expression levels of key genes involved in cell proliferation and survival. Forced expression of artemin did not alter or minimally altered the expression of most cell cycle-related markers, including cyclin D1 and E1, ATM, CDC25A, and CDK 2 and 4, but did significantly decrease the expression of cyclin-dependent kinase inhibitor-2A (CDKN2A) (Supplementary Table S3 , Supplementary data 2). CDKN2A, encoding p16 (INK4a), is a tumor suppressor gene that induces G 1 cell cycle arrest by inhibiting the phosphorylation of Rb protein by the cyclin-dependent kinases, CDK4 and CDK6 (Stott et al., 1998) . The expression of BCL2 in MCF7-ARTN cells was increased 8.4-fold compared with control MCF7-Vec cells. BCL2 is a well-described cell survival gene (Zinkel et al., 2006) . Another gene significantly increased by artemin was telomerase-reverse transcriptase (TERT). TERT, in addition to its role in immortalization, also suppresses apoptosis (Zhang et al., 2003) . It is noted that g-synuclein (SNCG, also referred as breast cancer-specific gene 1) was upregulated 1.67-fold by artemin. SNCG has been observed to protect tumor cells from apoptosis and to stimulate cell motility and metastasis (Wu et al., 2003) .
Forced expression of artemin promoted anchorageindependent growth
The effect of forced expression of artemin on anchorageindependent growth was examined in suspension culture and by colony formation in soft agar. MCF7-ARTN cells increased in number faster than did control MCF7-Vec cells in suspension culture (Figure 3a) , with a 42% increase in total cell number relative to MCF7-Vec after 10 days (Po0.01). In soft agar, the number of colonies formed by MCF7-ARTN cells was increased twofold (Po0.001) compared with MCF7-Vec cells ( Figure 3b ). MCF7-ARTN cells and control MCF7-Vec cells were also cultured in three-dimensional Matrigel. Concordant with colony formation in soft agar, an increase in colony number was observed for MCF7-ARTN cells compared with MCF7-Vec cells (data not shown). Moreover, the colonies formed by MCF7-ARTN cells in Matrigel were larger and the cells in those colonies were more motile and invasive compared with colonies formed by MCF7-Vec cells (Figure 3c ). MCF7-Vec cells produced circumscribed colonies, whereas a large number of MCF7-ARTN cells spread from the main bulk of the colony, suggesting that artemin promoted local invasive behavior.
Forced expression of artemin enhanced cell migration and invasion Fluorescence microscopy to visualize filamentous actin revealed that MCF7-Vec cells grew in clumps with prominent cell-to-cell contact typical of an epithelial phenotype, whereas MCF7-ARTN cells were scattered and displayed little intercellular contact (Figure 3d ). The effects of artemin on cell motility were therefore evaluated, first by the use of the standard Transwell chamber (BD Falcon, Franklin Lakes, NJ, USA) and subsequently by wound healing assay. Twice as many MCF7-ARTN cells migrated through Transwell inserts in 24 h than did control MCF7-Vec cells (Figure 3e ). In Transwell chambers coated with Matrigel, the invasive capacity of MCF7-ARTN cells over 48 h was enhanced 1.5-fold compared with control MCF7-Vec cells (Figure 3e ). In the wound-healing assay (Figure 3f ), MCF7-ARTN cells in monolayer culture showed complete wound healing within 72 h, whereas MCF7-Vec cells did not. Forced expression of artemin therefore enhanced the motility and invasive capacity of MCF-7 cells. Concordant with this observation, real-time PCR showed that forced expression of artemin significantly increased the expression of a number of genes involved in invasion and metastasis, including MMP1 (matrix metalloproteinase 1; by 7.6-fold), PLAU (3.8-fold) and SERPINE1 (3.1-fold) (Supplementary Table S3 , Supplementary data 2).
Forced expression of artemin promoted MCF-7 tumor xenograft growth in vivo To determine whether artemin enhances tumorigenicity in vivo, we used a xenograft model of MCF-7 cells injected into the mammary fat pad of immunodeficient nude mice. Both MCF7-ARTN and MCF7-Vec cells formed palpable and measurable tumors, but tumors formed by MCF7-ARTN were larger than those formed by control MCF7-Vec cells (Figure 4a ). Statistically significant enhancement of tumor volume was achieved on week 2 (P ¼ 0.023), and tumors formed by MCF7-ARTN cells were more than double the size of tumors formed by MCF7-Vec cells after 6.5 weeks.
MCF-7 is a rather well-differentiated tumor cell line, as reflected by its estrogen-dependent growth. Histology with hematoxylin and eosin staining showed that tumors formed by MCF7-Vec cells were well differentiated (left panel, Figure 4b ), whereas those formed by MCF7-ARTN cells were poorly differentiated (right panel, Figure 4b ). Unlike control MCF7-Vec cells, nuclei of which were regularly shaped and uniform with a clear cytoplasmic boundary, MCF7-ARTN cells were small spindle-shaped pleomorphic cells with irregular hyperchromatic nuclei, indistinct cytoplasmic borders and scanty cytoplasm.
To quantify proliferation and apoptosis within the tumor, BrdU incorporation and TUNEL (terminal doxynucleotidyl transferase-mediated dUTP nick end) labeling were carried out on tumor sections. Unlike monolayer culture in vitro (Figure 2e ), the MCF7-ARTN tumors exhibited a higher percentage of BrdUlabeled nuclei compared with MCF7-Vec tumors (Figure 4c ). TUNEL labeling to assess apoptosis also showed that artemin enhanced tumor cell survival, as there were significantly fewer TUNEL-positive cells in the MCF7-ARTN tumors compared with the MCF7-Vec tumors (Figure 4d ).
Forced expression of artemin enhanced anchorageindependent growth, cell migration and invasion in T47D and BT549 cells We also stably forced the expression of artemin in ER þ T47D and ERÀ BT549 cells (Figure 5a ). Both T47D-ARTN and BT549-ARTN cells with forced expression of artemin exhibited significant increases in colony formation in soft agar and in migration and invasion in Transwell assays compared with their respective control T47D-Vec and BT549-Vec cells (Figures 5b-d) . The effects were more pronounced in BT549 cells than in T47D cells. T47D-ARTN cells formed 35% more colonies than did control T47D-Vec cells in soft agar, whereas BT549-ARTN cells formed 64% more colonies than did control BT549-Vec cells (Figure 5b) . Enhancement of migration and invasion by forced expression of artemin amounted to 37 and 74%, respectively, in T47D cells and to 272 and 169%, respectively, in BT549 cells (Figures 5c and d ). BT549 cells with forced expression of artemin exhibited a more scattered, and mesenchymal morphology compared with the control cells (Figure 5e ).
Correlation of artemin expression with cancer type and clinical outcome
To determine the clinical relevance of artemin expression in human mammary carcinoma, we first used the Oncomine cancer microarray database to analyse the expression profile of artemin in a variety of human cancers. Please refer to Supplementary data 3 for tabulation and discussion of the findings from this database.
Immunohistochemical analysis of artemin in breast cancer and correlation of artemin expression to overall survival Immunohistochemical analysis showed that artemin protein expression in breast cancer tissue was significantly increased compared with normal tissue (Po0.001). In total, 65.4% (104 out of 159) of breast cancer samples exhibited positive artemin immunoreactivity compared with only 21.4% (3 out of 14) for the corresponding normal breast tissue (Supplementary  Table S7 , Supplementary data 4). As observed in Figures 6a-c , immunoreactivity was observed predominantly in the cytoplasm of tumor cells. Normal epithelial cells of mammary duct and acini and smooth muscle cells of blood vessels sometimes exhibited variable intensities of artemin immunoreactivity.
Artemin expression was observed to be significantly correlated to higher tumor stages (P ¼ 0.032) and was also highly correlated to HER2/neu (c-erbB-2) positivity (P ¼ 0.001) (Supplementary Table S8 , Supplementary data 4). However, no association of artemin expression was observed with age of the patient and tumor size, nor grade, ER or progesterone receptor status of the tumor. Significant correlation of increased artemin expression to decreased overall survival of patients was observed (P ¼ 0.021, Figure 6d ). An analysis of artemin expression in matched stage and HER2 status in patients are presented in Supplementary  Table S9 , Supplementary data 4. Only in HER2-positive patients, was artemin expression not significantly correlated to the outcome.
Depletion of endogenous artemin by siRNA significantly increased apoptotic cell death Next, we depleted MCF-7 cells of endogenous artemin with small interfering RNA (siRNA) and examined the effects on cellular behavior. To determine the depletion efficacy of the siRNA, artemin cDNA was inserted within the 3 0 UTR of an enhanced green fluorescent protein (EGFP) expression vector (pEGFP-ARTN) and the efficiency of siRNA in targeting the artemin transcript could be determined by examination of the expression level of EGFP protein by fluorescence microscopy. One of the artemin-specific siRNA constructs effectively reduced the fluorescence of EGFP in cells transiently transfected with pEGFP-ARTN compared with the siRNA-negative control plasmid (data not shown). The artemin-specific siRNA did not reduce EGFP expression in pEGFP-transfected cells compared with the siRNA-negative control (data not shown). Two stable MCF-7 cell lines, MCF7-siRNA and MCF7-CK, were established by stable transfection of the arteminspecific siRNA plasmid (pSilencer-ARTN) and the negative control plasmid (pSilencer-CK), respectively. The artemin expression level in these two cell lines was determined by both RT-PCR and Western blot, showing that endogenous expression of artemin was reduced in MCF7-siRNA cells at both the mRNA and protein levels compared with the control MCF7-CK cells (Figure 7a) . Depletion of endogenous artemin by siRNA did not affect MCF-7 cell number in serum-replete conditions, but significantly inhibited (by 20%) growth in serumreduced (0.2%) conditions (Figures 7b and c) . As expected, depletion of endogenous artemin by siRNA significantly increased apoptotic cell death induced by serum deprivation. On the basis of nuclear morphology after Hoechst 33258 visualization, 13% of MCF7-CK cells versus 20% of MCF7-siRNA cells were identified as apoptotic after serum deprivation for 24 h (Figure 7d ). Similar changes were observed when apoptosis was assessed by annexin-V labeling. The proportion of apoptotic cells in MCF7-siRNA cells was twice that in MCF7-CK cells (Figure 7e ). Of these apoptotic cells, the ratio of early apoptosis to late apoptosis was approximately 1 to 2.47 (1.9 versus 4.7%) for MCF7-siRNA cells and 1 to 3.71 (0.7 versus 2.6%) for MCF7-CK cells, providing further support for an inverse relationship between artemin expression and induction of apoptosis.
Depletion of endogenous artemin by siRNA significantly inhibited anchorage-independent growth in MCF-7 cells siRNA-mediated depletion of artemin in MCF-7 cells inhibited their anchorage-independent growth. The number of colonies formed by MCF7-siRNA cells in soft agar was significantly reduced (by 28.5%, Po0.001) compared with that of control MCF7-CK cells (Figure 8a ). Polyclonal antibody inhibition of artemin also significantly reduced (35%, Po0.001) soft agar colony formation in MCF-7 cells compared with control IgG (data not shown). Similar results were also obtained with a second polyclonal antibody generated in chicken (data not shown). When grown in three-dimensional Matrigel, a decrease in colony number was also observed for MCF7-siRNA cells compared with MCF7-CK cells (data not shown). The morphology of colonies formed by MCF7-siRNA cells in Matrigel differed from that of MCF7-CK cells (Figure 8b ). Artemin-depleted MCF7-siRNA cells formed small and shrunken colonies, whereas the control MCF7-CK cells formed larger and more voluminous colonies.
Depletion of endogenous artemin by siRNA and antibody impaired cell migration and invasion
We assessed whether depletion of endogenous artemin would impair the motility and/or invasiveness of MCF-7 cells. The numbers of cells that migrated through the non-coated (migration) or Matrigel-coated (invasion) porous filters of Transwell inserts were both significantly reduced in artemin-depleted MCF7-siRNA cells compared with control MCF7-CK cells (Figure 8c ). Artemin-depleted MCF7-siRNA cells also displayed a significant reduction in wound-induced migration, as wounds created in a monolayer of MCF7-siRNA cells closed less rapidly than did wounds in monolayers of MCF7-CK cells (Figure 8d) . Consistent with the effect of siRNA, a rabbit polyclonal antibody raised against artemin inhibited MCF-7 cell invasion in a dosedependent manner (Figure 8e) , with 51.3 and 74.6% reductions observed at antibody concentrations of 200 and 400 mg/ml, respectively. Further increases in antibody concentration did not enhance this effect. Similar results were also obtained with a second polyclonal antibody generated in chicken (data not shown).
Discussion
Herein, we have identified artemin as a functionally and clinically validated molecule involved in human mammary neoplastic progression. Functional inhibition of artemin signaling pathways may therefore constitute a targeted therapeutic approach to ameliorate human mammary carcinoma. Targeting of artemin itself may be preferable for a number of reasons. GFLs are promiscuous both in their binding to the four described GFRa isoforms (Bespalov and Saarma, 2007) and in the signaling receptors they use (RET, NCAM, Syndecan and Met) (Takahashi, 2001; Paratcha et al., 2003; Sariola and Saarma, 2003) . For example, GFRa1 and RET were co-expressed in 18% of mammary carcinomas studied (Esseghir et al., 2007) , whereas 42% of mammary carcinomas were GFRa1-positive and RETnegative. Thus, specific targeting of RET alone would not be efficacious in GFL-dependent mammary carcinoma. Similarly, specific targeting of the individual GFRa isoforms may not be efficacious in abrogating GFL signaling in mammary carcinoma, as other GFRa isoforms may compensate for the inhibition allowing escape and development of resistance. For example, expression of GFRa3 is increased in tamoxifen-resistant mammary carcinoma cells treated with gefitinib, which targets the EGF receptor (Hutcheson et al., 2006) . Furthermore, it is not yet clear whether the GFRa isoforms are the only receptors/binding proteins for GFLs; GFLs may also bind to NCAM, albeit with low affinity (Sariola and Saarma, 2003) , or require other cell surface proteins, such as heparin sulfate glycosaminoglycans (Sariola and Saarma, 2003) , for signaling. Other proteins, such as GAS1 (Schueler-Furman et al., 2006) , also share homology with GFRa and may function as GFL-receptors/binding proteins. Further, at least from data published to date, GFRa expression is not correlated with patient survival, although expression is Oncogenic properties of artemin J Kang et al correlated with lymphovascular invasion and lymph node metastasis of the carcinoma (Esseghir et al., 2007) . In contrast, artemin expression is highly and significantly associated with multiple outcome variables in mammary carcinoma including survival (see Supplementary Tables S4 and S5 , Supplementary data 3). Although GDNF may exert similar functional effects in mammary carcinoma cells (Esseghir et al., 2007) , it may not be as clinically relevant as artemin because it (currently) lacks the multiple highly significant correlations (Supplementary Table S6 , Supplementary data 3) with disease and outcome observed for artemin. Of the proteins in the GFL-GFRa axis, artemin may therefore be the preferred therapeutic target. We have provided evidence that targeting of artemin with either specific siRNA or antibody will reduce the oncogenic characteristics of mammary carcinoma cells. Consideration should therefore be given to the development of novel therapeutics targeting artemin for use in arteminexpressing and -dependent tumors.
Unlike monolayer culture in vitro MCF7-ARTN xenografts exhibited a higher percentage of BrdUlabeled nuclei compared with those derived from MCF7-Vec cells. It has been widely recognized that the tumor microenvironment plays a major role in dictating tumor behavior and progression, as well as response to therapy (Lubaroff et al., 1980; Chung, 1993; Pettaway et al., 1996; Singh et al., 2007) . Indeed, mammary stromal fibroblasts have been shown both in vitro and in vivo to modulate mammary carcinoma cell proliferation (Brouty-Boye and Raux, 1993; Sadlonova et al., 2005) . Therefore, the ARTN stimulated increase in BrdU-positive cells in vivo, but not in vitro, is indicative that artemin also possesses stromal or paracrine interactions in vivo. Such in vitro versus in vivo differences have been observed for other oncogenic molecules (Anderson et al., 2001; Duxbury et al., 2004) . In this regard, it is interesting that syndecan, a GFL binding protein (Sariola and Saarma, 2003) , shed by stromal fibrobalsts, stimulates human mammary carcinoma cell proliferation (Su et al., 2007) .
We note some discrepancies in the correlation of artemin mRNA expression to clinicopathological parameters in the Oncomine database compared with the immunohistopathological data for artemin generated herein. This discrepancy may simply be indicative of differences inherent in measurement of artemin mRNA versus artemin protein and compounded by the fact that In summary, we have shown the oncogenic properties of artemin in mammary carcinoma cells in vitro as well as in xenograft models in vivo. Together with the highly significant clinical association of artemin expression with disease outcome, artemin is thus identified as a potential therapeutic target in oncology.
Materials and methods
Plasmid constructs
The coding sequence for human artemin transcript variant 4 (GenBank accession number NM_057090) was cloned into the mammalian expression vector pIRESneo3 (Invitrogen, Carlsbad, CA, USA), designated as pIRESneo3-ARTN. To visualize the depletion efficiency of siRNA, we inserted the artemin cDNA into the 3 0 UTR of an EGFP expression vector pEGFP-C1, designated as pEGFP-ARTN. The cDNA fragment coding for the mature artemin peptide of 113 amino acids was cloned into the pGEX-4T1 vector (Amersham Biosciences, Piscataway, NJ, USA) in frame with the N-terminal glutathione-S-transferase to generate pGEX-4T1-ARTN plasmid for the expression of glutathione-S-transferase fusion proteins in E. coli. To generate siRNA oligonucleotides targeting all four variants of artemin, the DNA sequence 5 0 -AACTGGCCTG TACTCACTCAT-3 0 was selected to construct an siRNA expression plasmid using the pSilencer 2.1-U6 hygro vector (Ambion, Austin, TX, USA) according to the manufacturer 0 s protocol. The resultant vector was designated as pSilencer-ARTN. The negative control siRNA plasmid (pSilencer-CK) encodes an siRNA, which has no significant sequence similarity to human gene sequences (Ambion).
Cell culture
All cell lines used in this study were obtained from the ATCC (American Type Culture Collection) and cultured in conditions as recommended. MCF-7, T47D and BT549 cells were stably transfected with pIRESneo3-ARTN or the empty pIRESneo3 vector plasmids to establish stable cell lines MCF7-ARTN, T47D-ARTN and BT549-ARTN with forced expression of artemin and their control cell lines MCF7-Vec, T47D-Vec and BT549-Vec, respectively. Similarly, MCF-7 cells were stably transfected with pSilencer-ARTN and pSilencer-CK plasmids to obtain MCF7-siRNA and MCF7-CK cells, respectively.
PCR, RT-PCR and real-time PCR PCR, RT-PCR and real-time PCR were performed as described earlier (Pandey et al., 2008 ) (see Supplementary data 1 and 2).
Western blot analysis
Western blot analysis was carried out as described earlier (Liu and Lobie, 2007) using the following antibodies: goat antiartemin polyclonal antibody (R&D Systems, Minneapolis, MN, USA) and a monoclonal antibody against b-actin (Sigma, St Louis, MO, USA).
Cell death, proliferation and oncogenicity assays Apoptotic analysis was carried out as described earlier (Zhu et al., 2005) . Other biological assays such as total cell number, MTT assay, BrdU incorporation, anchorage-independent growth (soft agar and suspension culture), three-dimensional morphogenesis, in vitro cell motility (migration, invasion and wound healing) assays were carried out as described (Pandey et al., 2008) .
Tumor xenografts in nude mice
Tumor xenograft growth in vivo was essentially as described earlier (Zhu et al., 2005) . MCF7-ARTN and MCF7-Vec cells were injected subcutaneously into the mammary fat pad of 3-to 4-week-old BALBc nu/nu mice (Shanghai Slaccas Co., Shanghai, China) (n ¼ 8 for each). Histological analysis with hematoxylin and eosin (H&E), and BrdU and TUNEL immunostaining were carried out as described (Pandey et al., 2008) . Production of recombinant protein and generation of antibody Recombinant artemin protein was expressed and purified in E. coli using glutathione-S-transferase tag from pGEX-4T1-ARTN plasmid as described (Masure et al., 1999) and was used to generate a rabbit polyclonal antibody.
Statistics
All experiments were repeated three to five times. All numerical data are expressed as mean±s.e.m. (standard error of the mean) from a representative experiment performed in triplicate, and statistical analyses were assessed by Student's t test using Microsoft Excel XP.
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